Free Trial
NASDAQ:OCS

Oculis (OCS) Stock Price, News & Analysis

Oculis logo
$17.18
+0.01 (+0.06%)
(As of 10/31/2024 ET)

About Oculis Stock (NASDAQ:OCS)

Key Stats

Today's Range
$17.04
$17.58
50-Day Range
$11.85
$17.17
52-Week Range
$9.05
$17.58
Volume
44,499 shs
Average Volume
35,543 shs
Market Capitalization
$695.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.20
Consensus Rating
Buy

Company Overview

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Oculis Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
38th Percentile Overall Score

OCS MarketRank™: 

Oculis scored higher than 38% of companies evaluated by MarketBeat, and ranked 770th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oculis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Oculis has only been the subject of 1 research reports in the past 90 days.

  • Read more about Oculis' stock forecast and price target.
  • Earnings Growth

    Earnings for Oculis are expected to decrease in the coming year, from ($2.19) to ($2.21) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oculis is -8.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oculis is -8.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oculis has a P/B Ratio of 5.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Oculis' valuation and earnings.
  • Percentage of Shares Shorted

    0.18% of the float of Oculis has been sold short.
  • Short Interest Ratio / Days to Cover

    Oculis has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oculis has recently increased by 133.68%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Oculis does not currently pay a dividend.

  • Dividend Growth

    Oculis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.18% of the float of Oculis has been sold short.
  • Short Interest Ratio / Days to Cover

    Oculis has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oculis has recently increased by 133.68%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Oculis has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Oculis this week, compared to 2 articles on an average week.
  • Search Interest

    4 people have searched for OCS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oculis insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Only 22.30% of the stock of Oculis is held by institutions.

  • Read more about Oculis' insider trading history.
Receive OCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter.

OCS Stock News Headlines

Protect Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Oculis accelerates patient enrollment for both Phase 3 DIAMOND trials
See More Headlines

OCS Stock Analysis - Frequently Asked Questions

Oculis' stock was trading at $11.23 at the start of the year. Since then, OCS stock has increased by 53.0% and is now trading at $17.18.
View the best growth stocks for 2024 here
.

Oculis Holding AG (NASDAQ:OCS) posted its quarterly earnings results on Tuesday, August, 27th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.13. The business had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.28 million. Oculis had a negative net margin of 7,679.05% and a negative trailing twelve-month return on equity of 61.33%.

Top institutional shareholders of Oculis include abrdn plc (2.03%).

Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oculis investors own include SoFi Technologies (SOFI), Meta Platforms (META), Bitdeer Technologies Group (BTDR), Purpose Bitcoin ETF (BTCC.B), Booz Allen Hamilton (BAH), Broadcom (AVGO) and Atara Biotherapeutics (ATRA).

Company Calendar

Last Earnings
8/27/2024
Today
10/31/2024
Next Earnings (Estimated)
11/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OCS
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$29.20
High Stock Price Target
$37.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+70.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-98,920,000.00
Net Margins
-7,679.05%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$980,000.00
Book Value
$2.87 per share

Miscellaneous

Free Float
N/A
Market Cap
$694.24 million
Optionable
Not Optionable
Beta
0.30
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:OCS) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners